EP1613621A1 - Prostaglandin analoge als ep4 rezeptor agonisten - Google Patents

Prostaglandin analoge als ep4 rezeptor agonisten

Info

Publication number
EP1613621A1
EP1613621A1 EP04723484A EP04723484A EP1613621A1 EP 1613621 A1 EP1613621 A1 EP 1613621A1 EP 04723484 A EP04723484 A EP 04723484A EP 04723484 A EP04723484 A EP 04723484A EP 1613621 A1 EP1613621 A1 EP 1613621A1
Authority
EP
European Patent Office
Prior art keywords
hydroxy
enyl
difluoro
phenylbut
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP04723484A
Other languages
English (en)
French (fr)
Other versions
EP1613621B1 (de
Inventor
Xavier Billot
John Colucci
Yongxin Han
Marie-Claire Wilson
Robert N. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Publication of EP1613621A1 publication Critical patent/EP1613621A1/de
Application granted granted Critical
Publication of EP1613621B1 publication Critical patent/EP1613621B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • C07D211/76Oxygen atoms attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/061,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/081,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/101,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • Glaucoma is a degenerative disease of the eye wherein the intraocular pressure is too high to permit normal eye function. As a result, damage may occur to the optic nerve head and result in irreversible loss of visual function. If untreated, glaucoma may eventually lead to blindness. Ocular hypertension, i.e., the condition of elevated intraocular pressure without optic nerve head damage or characteristic glaucomatous visual field defects, is now believed by the majority of ophthalmologists to represent merely the earliest phase in the onset of glaucoma.
  • disorders in humans and other mammals involve or are associated with abnormal or excessive bone loss.
  • Such disorders include, but are not limited to, osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, bone fractures, rheumatoid arthritis, periprosthetic osteolysis, osteogenesis imperfecta, metastatic bone disease, hypercalcemia of malignancy, and multiple myeloma.
  • osteoporosis which in its most frequent manifestation occurs in postmenopausal women.
  • Prostaglandins such as the PGE2 series are known to stimulate bone formation and increase bone mass in mammals, including man.
  • EPj The major prostaglandin receptor in bone
  • EP4 The major prostaglandin receptor in bone is EP4, which is believed to provide its effect by signaling via cyclic AMP.
  • formula I agonists of the EP4 subtype receptor are useful for stimulating bone formation.
  • This invention relates to agonists of the EP4 subtype of prostaglandin E2 receptors and their use or a formulation thereof in the treatment of glaucoma and other conditions that are related to elevated intraocular pressure in the eye of a patient.
  • this invention relates to a series of 1,6-disubstituted piperidin-2-one, 3,4-disubstituted 1,3-oxazinan- 2-one, 3,4-disubstituted l,3-thiazinan-2-one, and 4,5-disubstituted morpholin-3-one derivatives and their use to treat ocular diseases and to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
  • This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
  • this invention relates to novel EP4 agonist having the structural formula I:
  • Q is (CH 2 ) m , (CH2) C6-10aryl> (CH 2 ) m C5-io heterocyclyl, (CH2) C3-10 heterocycloalkyl, (CH2)mC3-8 cycloalkyl, C(halo)2 said cycloalkyl, heterocycloalkyl, aryl or heterocyclyl unsubstituted or substituted with 1-3 groups of Ra ;
  • X and Y independently represent CH 2 , O, NR 9 or S, provided however, that X and Y are not O,
  • Rl represents (CH2)phydroxy, (CH2)pCN, (CH 2 ) p CO2RlO, (CH 2 ) n SO3R 6 , - (CH 2 )pCF2SO2NH2, -(CH 2 ) p SO2NH2, -(CH2)pCONHSO 2 R2, -(CH2)pSO2NHCOR2, -(CH2) p PO(OH)2, (CH2)pCONHPO2R6, (CH2) p CONHR8, (CH 2 ) p Ci-4alkoxy, -(CH2)pcycloalkyl 3 (CH2)p-hydroxymethylketone or (CH2)nheterocyclyl, sa id heterocyclyl unsubstituted or substituted with 1 to 3 groups of Ra and optionally containing an acidic hydroxyl group;
  • R 2 independently represents CMO alkyl, (CH2) m C6-lQaryl,
  • R3 and R4 independently represents hydrogen, halogen, or C ⁇ _6 alkyl, or R3 and R4 may be taken together to form a 3-7 membered carbon ring optionally interrupted with 1-2 heteroatoms chosen from O, S, SO, SO2, and NR9.
  • R6 and R7 independently represents hydrogen, or C ⁇ _4 alkyl
  • R8 represents hydrogen, acyl, or sulfonyl
  • R9 represents hydrogen, C 1-6 alkyl, said alkyl optionally substituted with 1-3 halogen, CN, OH, C ⁇ -6 alkoxy, C 1-6 acyloxy or amino;
  • RlO represents hydrogen, Ci-io alkyl, C3-.10 cyclcoalkyl, (CH2)pC6-10 aryl, (CH2)pC5_io heterocyclyl, CR6R7OC(O)O C3.10 cycloalkyl or CR6R7OC(O)O Ci-io alkyl;
  • R b represents hydrogen, Cl-6 alkyl or halogen
  • R a represents C ⁇ _6 alkoxy, C ⁇ _6 alkyl, CFs, nitro, amino, cyano, Cl- alkylamino, halogen, or Ra further represents for aryls and heterocyclyl, SCi_6alkyl, SC ⁇ -lOary ⁇ SC5_ ⁇ oheterocyclyl, CO2 6 , OC6-10aryl, OCs-iohetetoc clyl, CH2OC1-6 alkyl, CH2SC1-6 alkyl, CH2 ⁇ a ⁇ yl, CH2Saryl;
  • p 0-3
  • n 0-4;
  • n 0-8.
  • terapéuticaally effective amount means that amount of the EP4 receptor subtype agonist of formula I, or other actives of the present invention, that will elicit the desired therapeutic effect or response or provide the desired benefit when administered in accordance with the desired treatment regimen.
  • a preferred therapeutically effective amount relating to the treatment of abnormal bone resorption is a bone formation, stimulating amount.
  • a preferred therapeutically effective amount relating to the treatment of ocular hypertension or glaucoma is an amount effective for reducing intraocular pressure and/or treating ocular hypertension and/or glaucoma.
  • “Pharmaceutically acceptable” as used herein means generally suitable for administration to a mammal, including humans, from a toxicity or safety standpoint.
  • prodrug refers to compounds which are drug precursors which, following administration and absorption, release the claimed drug in vivo via some metabolic process.
  • a non-limiting example of a prodrug of the compounds of this invention would be an acid of the pyrrolidinone group, where the acid functionality has a structure that makes it easily hydrolyzed after administration to a patient.
  • exemplary prodrugs include acetic acid derivatives that are non-narcotic, analgesics/non-steroidal, anti-inflammatory drugs having a free CH2COOH group (which can optionally be in the form of a pharmaceutically acceptable salt, e.g. -CH2COO-Na+), typically attached to a ring system, preferably to an aromatic or heteroaromatic ring system.
  • alkyl refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 10 carbon atoms unless otherwise defined. It may be straight, branched or cyclic. Preferred alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, cyclopentyl and cyclohexyl. When the alkyl group is said to be substituted with an alkyl group, this is used interchangeably with "branched alkyl group”.
  • Cycloalkyl is a species of alkyl containing from 3 to 15 carbon atoms, without alternating or resonating double bonds between carbon atoms. It may contain from 1 to 4 rings, which are fused. Examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • Alkoxy refers to C j -Cg alkyl-O-, with the alkyl group optionally substituted as described herein. Examples of alkoxy groups are methoxy, ethoxy, propoxy, butoxy and isomeric groups thereof.
  • Halogen (halo) refers to chlorine, fluorine, iodine or bromine.
  • Aryl refers to aromatic rings e.g., phenyl, substituted phenyl and the like, as well as rings which are fused, e.g., naphthyl, phenanthrenyl and the like.
  • An aryl group thus contains at least one ring having at least 6 atoms, with up to five such rings being present, containing up to 22 atoms therein, with alternating (resonating) double bonds between adjacent carbon atoms or suitable heteroatoms.
  • the preferred aryl groups are phenyl, naphthyl and phenanthrenyl.
  • Aryl groups may likewise be substituted as defined.
  • Preferred substituted aryls include phenyl and naphthyl.
  • heterocycloalkyl refers to a cycloalkyl group (nonaromatic) having 3 to 10 carbon atoms in which one of the carbon atoms in the ring is replaced by a heteroatom selected from O, S or N, and in which up to three additional carbon atoms may be replaced by hetero atoms.
  • cycloalkyl refers to a cyclic alkyl group (nonaromatic) having 3 to 10 carbon atoms.
  • heteroatom means O, S or N, selected on an independent basis.
  • heteroaryl refers to a monocyclic aromatic hydrocarbon group having
  • ring atoms or a bicyclic aromatic group having 8 to 10 atoms, containing at least one heteroatom, O, S or N, in which a carbon or nitrogen atom is the point of attachment, and in which one or two additional carbon atoms is optionally replaced by a heteroatom selected from O or S, and in which from 1 to 3 additional carbon atoms are optionally replaced by nitrogen heteroatoms, said heteroaryl group being optionally substituted as described herein.
  • this type are pyrrole, pyridine, oxazole, thiazole, tetrazole, and oxazine.
  • the tetrazole includes all tautomeric forms.
  • heterocyclyl or heterocyclic represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom, which results in the creation of a stable structure.
  • a fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.
  • the term heterocycle or heterocyclic includes heteroaryl moieties. Examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnoUnyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, 1,3-dioxolanyl, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolin
  • heterocyclyls containing acidic hydroxyl groups are those heterocyclyl groups that have an acidic hydroxy atom and can have a pKa in the range of 3 to 7.
  • agonist means EP4 subtype compounds of formula I interact with the EP4 receptor to produce maximal, super maximal or submaximal effects compared to the natural agonist, PGE2. See Goodman and Gilman, The Pharmacological Basis of Therapeutics, 9 th edition, 1996, chapter 2.
  • Rl is (CH2)pCN
  • (CH2)pCONHR8, or (CH2) n heterocyclyl S s ⁇ d heterocyclyl unsubstituted or substituted with 1 to 3 groups of Ra and all other variables are as originally described.
  • a subembodiment of this invention is realized when Z is a (C(Rb)2) n .
  • Another subembodiment of this invention is when Z is Sulfur.
  • Rl is (CH2)pCO2R O, and Z is sulfur, the sulfur is hexavalent.
  • Another embodiment of this invention is when Z is O.
  • Rl is (CH2)pCO2RlO and all other variables are as originally described.
  • a subembodiment of this invention is realized when X and Y are CH2, Z is (C(Rb)2)n, Q is (CH2)m, R3 and R4 are halogen and all other variables are as originally described.
  • Rl is (CH2)mC5- lOheterocyclyl, said heterocyclyl unsubstituted or substituted with 1 to 3 groups of Ra and all other variables are as originally described.
  • a subembodiment of this invention is realized when Z is a (C(Rb)2)n-
  • Z is S.
  • Another embodiment of this invention is when Z is O.
  • R2 is (CH2)mC6-10aryl, said aryl unsubstituted or substituted with 1 to 3 groups of Ra and all other variables are as originally described.
  • a sub-embodiment of this invention is realized when Rl is (CH2)pCO2RlO, - (CH 2 ) p PO(OH)2, (CH2)pCONHPO 2 R6, (CH2)pCONHR8, or (CH2)p-tetrazolyl said tetrazolyl unsubstituted or substituted with a Ra group and all other variables are as originally described.
  • a subembodiment of this invention is realized when Z is a (C(Rb)2) n .
  • Another subembodiment of this invention is realized when Z is realized when Z is
  • Another embodiment of this invention is when Z is O.
  • a subembodiment of this invention is realized when Z is a (C(Rb)2) n .
  • Another subembodiment of this invention is realized when Z is S. Another embodiment of this invention is when Z is O.
  • Still another embodiment of this invention is realized when U is H and W is OH. Still another embodiment of this invention is realized when U is Cl-3 alkyl and W is OH.
  • Still another embodiment of this invention is realized when Q represents (CH2)n > or C(halo)2 and all other variables are as originally described.
  • a subembodiment of this invention is realized when Z is a (C(Rb)2) n .
  • Another subembodiment is realized when Z is S.
  • Still another embodiment of this invention is realized when Y represents CH2, X is O, S or CH2, W is OH, U is H or methyl, R3 is H, F or CH2 and R2 is phenyl, thienyl, naphthyl, benzothioenyl, benzofuranyl, or biphenyl, said phenyl, thienyl, naphthyl, benzothioenyl, benzofuranyl, or biphenyl unsubstituted or substituted with 1-3 groups of R a and all other variables are as originally described.
  • Compounds of this invention are: 7- ⁇ (2i?)-2-[(lE,3i?)-4,4-difluoro-3-hydroxy-4-phenylbut-l-enyl]-6-oxopiperidin-l-yl ⁇ heptanoic acid;
  • Another embodiment of this invention is directed to a composition containing an ⁇ P4 agonist of Formula I and optionally a pharmaceutically acceptable carrier.
  • Yet another embodiment of this invention is directed to a method for decreasing elevated intraocular pressure or treating glaucoma by administration, preferably topical or intra- camaral administration, of a composition containing an EP4 agonist of Formula I and optionally a pharmaceutically acceptable carrier.
  • administration preferably topical or intra- camaral administration
  • a composition containing an EP4 agonist of Formula I and optionally a pharmaceutically acceptable carrier is also included in this invention.
  • This invention is further concerned with a process for making a pharmaceutical composition comprising a compound of formula I.
  • This invention is further concerned with a process for making a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I, and a pharmaceutically acceptable carrier.
  • the claimed compounds bind strongly and act on PGE2 receptor, particularly on the EP4 subtype receptor and therefore are useful for preventing and/or treating glaucoma and ocular hypertension.
  • Dry eye is a common ocular surface disease afflicting millions of people. Although it appears that dry eye may result from a number of unrelated pathogenic causes, the common end result is the breakdown of the tear film, which results in dehydration of the exposed outer surface of the eye. (Lemp, Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes, The CLAO Journel, 21(4):221-231 (1995)).
  • Macular edema is swelling within the retina within the critically important central visual zone at the posterior pole of the eye. It is believed that EP4 agonist which lower IOP are useful for treating diseases of the macular such as macular edema or macular degeneration.
  • another aspect of this invention is a method for treating macular edema or macular degeneration.
  • Glaucoma is characterized by progressive atrophy of the optic nerve and is frequently associated with elevated intraocular pressure (IOP). It is possible to treat glaucoma, however, without necessarily affecting IOP by using drugs that impart a neuroprotective effect. See Arch. Ophthalmol. Vol. 112, Jan 1994, pp. 37-44; Investigative Ophthamol. & Visual Science, 32, 5, April 1991, pp. 1593-99. It is believed that EP4 agonist which lower IOP are useful for providing a neuroprotective effect. They are also believed to be effective for increasing retinal and optic nerve head blood velocity and increasing retinal and optic nerve oxygen by lowering IOP, which when coupled together benefits optic nerve health. As a result, this invention further relates to a method for increasing retinal and optic nerve head blood velocity, or increasing retinal and optic nerve oxygen tension or providing a neuroprotective effect or a combination thereof by using an EP4 agonist of formula I.
  • compositions which may be administered to mammals, including humans, to achieve effective IOP lowering are readily combined with suitable and known pharmaceutically acceptable excipients to produce compositions which may be administered to mammals, including humans, to achieve effective IOP lowering.
  • this invention is also concerned with compositions and methods of treating ocular hypertension, glaucoma, macular edema, macular degeneration, for increasing retinal and optic nerve head blood velocity, for increasing retinal and optic nerve oxygen tension, for providing a neuroprotective effect or for a combination thereof by administering to a patient in need thereof one of the compounds of formula I alone or in combination with one or more of the following active ingredients, a ⁇ -adrenergic blocking agent such as timolol, betaxolol, levobetaxolol, carteolol, levobunolol, a parasympathomimetic agent such as pilocarpine, a sympathomimetic agents such as epinephrine, iopidine,
  • 4,690,931 particularly eliprodil and R-eliprodil as set forth in WO 94/13275, including memantine; and/or an agonist of 5-HT2 receptors as set forth in PCT US00/31247, particularly l-(2-aminopropyl)-3- methyl-lH-imdazol-6-ol fumarate and 2-(3-chloro-6-methoxy-indazol-l-yl)-l-methyl- ethylamine.
  • the EP4 agonist used in the instant invention can be administered in a therapeutically effective amount intravaneously, subcutaneously, topically, transdermally, parenterally or any other method known to those skilled in the art.
  • Ophthalmic pharmaceutical compositions are preferably adapted for topical administration to the eye in the form of solutions, suspensions, ointments, creams or as a solid insert.
  • Ophthalmic formulations of this compound may contain from 0.001 to 5% and especially 0.001 to 0.1% of medicament. Higher dosages as, for example, up to about 10% or lower dosages can be employed provided the dose is effective in reducing intraocular pressure, treating glaucoma, increasing blood flow velocity or oxygen tension.
  • the pharmaceutical preparation which contains the compound may be conveniently admixed with a non-toxic pharmaceutical organic carrier, or with a non-toxic pharmaceutical inorganic carrier.
  • Typical of pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or aralkanols, vegetable oils, peanut oil, polyalkylene glycols, petroleum based jelly, ethyl cellulose, ethyl oleate, carboxymethyl-cellulose, polyvinylpyrrolidone, isopropyl myristate and other conventionally employed acceptable carriers.
  • water mixtures of water and water-miscible solvents such as lower alkanols or aralkanols, vegetable oils, peanut oil, polyalkylene glycols, petroleum based jelly, ethyl cellulose, ethyl oleate, carboxymethyl-cellulose, polyvinylpyrrolidone, isopropyl myristate and other conventionally employed acceptable carriers.
  • the pharmaceutical preparation may also contain non-toxic auxiliary substances such as emulsifying, preserving, wetting agents, bodying agents and the like, as for example, polyethylene glycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500, 4,000, 6,000 and 10,000, antibacterial components such as quaternary ammonium compounds, phenylmercuric salts known to have cold sterilizing properties and which are non- injurious in use, thimerosal, methyl and propyl paraben, benzyl alcohol, phenyl ethanol, buffering ingredients such as sodium borate, sodium acetates, gluconate buffers, and other conventional ingredients such as sorbitan monolaurate, triethanolamine, oleate, polyoxyethylene sorbitan monopalmitylate, dioctyl sodium sulfosuccinate, monothioglycerol, thiosorbitol, ethylenediamine tetracetic acid, and the like.
  • auxiliary substances such as e
  • suitable ophthalmic vehicles can be used as carrier media for the present purpose including conventional phosphate buffer vehicle systems, isotonic boric acid vehicles, isotonic sodium chloride vehicles, isotonic sodium borate vehicles and the like.
  • the pharmaceutical preparation may also be in the form of a microparticle formulation.
  • the pharmaceutical preparation may also be in the form of a solid insert. For example, one may use a solid water soluble polymer as the carrier for the medicament.
  • the polymer used to form the insert may be any water soluble non-toxic polymer, for example, cellulose derivatives such as methylcellulose, sodium carboxymethyl cellulose, (hydroxyloweralkyl cellulose), hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose; acrylates such as polyacrylic acid salts, ethylacrylates, polyactylamides; natural products such as gelatin, alginates, pectins, tragacanth, karaya, chondrus, agar, acacia; the starch derivatives such as starch acetate, hydroxymethyl starch ethers, hydroxypropyl starch, as well as other synthetic derivatives such as polyvinyl alcohol, polyvinyl pyrrolidone, polyvinyl methyl ether, polyethylene oxide, neutralized carbopol and xanthan gum, gellan gum, and mixtures of said polymer.
  • Suitable subjects for the administration of the formulation of the present invention include
  • the pharmaceutical preparation may contain non-toxic auxiliary substances such as antibacterial components which are non-injurious in use, for example, thimerosal, benzalkonium chloride, methyl and propyl paraben, benzyldodecinium bromide, benzyl alcohol, or phenylethanol; buffering ingredients such as sodium chloride, sodium borate, sodium acetate, sodium citrate, or gluconate buffers; and other conventional ingredients such as sorbitan rnonolaurale, triethanolamine, polyoxyethylene sorbitan monopalmitylate, ethylenediamine tetraacetic acid, and the like.
  • auxiliary substances such as antibacterial components which are non-injurious in use, for example, thimerosal, benzalkonium chloride, methyl and propyl paraben, benzyldodecinium bromide, benzyl alcohol, or phenylethanol
  • buffering ingredients such as sodium chloride, sodium borate, sodium acetate,
  • the ophthalmic solution or suspension may be administered as often as necessary to maintain an acceptable IOP level in the eye. It is contemplated that administration to the mammalian eye will be from once up to three times daily.
  • novel formulations of this invention may take the form of solutions, gels, ointments, suspensions or solid inserts, formulated so that a unit dosage comprises a therapeutically effective amount of the active component or some multiple thereof in the case of a combination therapy.
  • the compounds of the instant invention are also useful for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts. See PCT US99/23757 filed October 12, 1999 and incorporated herein by reference in its entirety.
  • the major prostaglandin receptor in bone is EP4, which is believed to provide its effect by signaling via cyclic AMP. See Ikeda T, Miyaura C, Ichikawa A, Narumiya S, Yoshiki S and Suda T 1995, In situ localization of three subtypes (EP j , EP3 and EP4) of prostaglandin E receptors in embryonic and newborn mice., I Bone Miner Res 10 (sup 1):S172, which is incorporated by reference herein in its entirety. Use of the compounds of formula I for the manufacture of a medicament for mediating the bone modeling and remodeling processes are also included in this invention.
  • another object of the present invention is to provide methods for stimulating bone formation, i.e. osteogenesis, in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype agonist of formula I. Still another object of the present invention to provide methods for stimulating bone formation in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of an EP4 receptor subtype agonist of formula I and a bisphosphonate active. Use of the compounds of formula I for the manufacture of a medicament for stimulating bone formation is also included in this invention. Yet another object of the present invention to provide pharmaceutical compositions comprising a therapeutically effective amount of an EP4 receptor subtype agonist of formula I and a bisphosphonate active.
  • Use of the compounds of formula I for the manufacture of a medicament for treating or reducing the risk of contracting a disease state or condition related to abnormal bone resorption is also included in this invention.
  • the disease states or conditions related to abnormal bone resorption include, but are not limited to, osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, bone fractures, rheumatoid arthritis, periprosthetic osteolysis, osteogenesis imperfecta, metastatic bone disease, hypercalcemia of malignancy, and multiple myeloma.
  • both concurrent and sequential administration of the EP4 receptor subtype agonist of formula I and the bisphosphonate active are deemed within the scope of the present invention.
  • the formulations are prepared containing 5 or 10 mg of a bisphosphonate active, on a bisphosphonic acid active basis.
  • the agonist and the bisphosphonate can be administered in either order.
  • the agonist and bisphosphonate are typically administered within the same 24 hour period.
  • the agonist and bisphosphonate are typically administered within about 4 hours of each other.
  • a non-limiting class of bisphosphonate actives useful in the instant invention are selected from the group consisting of alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, neridronate, olpandronate, risedronate, piridronate, pamidronate, zolendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.
  • a non-limiting subclass of the above-mentioned class in the instant case is selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.
  • a non-limiting example of the subclass is alendronate monosodium trihydrate.
  • the agonist is typically administered for a sufficient period of time until the desired therapeutic effect is achieved.
  • the term "until the desired therapeutic effect is achieved”, as used herein, means that the therapeutic agent or agents are continuously administered, according to the dosing schedule chosen, up to the time that the clinical or medical effect sought for the disease or condition being mediated is observed by the clinician or researcher.
  • the compounds are continuously administered until the desired change in bone mass or structure is observed. In such instances, achieving an increase in bone mass or a replacement of abnormal bone structure with normal bone structure are the desired objectives.
  • the compounds are continuously administered for as long as necessary to prevent the undesired condition. In such instances, maintenance of bone mass density is often the objective.
  • Nonlimiting examples of administration periods can range from about 2 weeks to the remaining lifespan of the mammal.
  • administration periods can range from about 2 weeks to the remaining lifespan of the human, preferably from about 2 weeks to about 20 years, more preferably from about 1 month to about 20 years, more preferably from about 6 months to about 10 years, and most preferably from about 1 year to about 10 years.
  • the instant compounds are also useful in combination with known agents useful for treating or preventing bone loss, bone fractures, osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, osteoarthritis, rheumatoid arthritis, periprosthetic osteolysis, osteogenesis imperfecta, metastatic bone disease, hypercalcemia of malignancy, and multiple myeloma.
  • Combinations of the presently disclosed compounds with other agents useful in treating or preventing osteoporosis or other bone disorders are within the scope of the invention.
  • a person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the disease involved.
  • Such agents include the following: an organic bisphosphonate; a cathepsin K inhibitor; an estrogen or an estrogen receptor modulator; an androgen receptor modulator; an inhibitor of osteoclast proton ATPase; an inhibitor of HMG- CoA reductase; an integrin receptor antagonist; an osteoblast anabolic agent, such as PTH; calcitonin; Vitamin D or a synthetic Vitamin D analogue; and the pharmaceutically acceptable salts and mixtures thereof.
  • a preferred combination is a compound of the present invention and an organic bisphosphonate. Another preferred combination is a compound of the present invention and an estrogen receptor modulator. Another preferred combination is a compound of the present invention and an estrogen. Another preferred combination is a compound of the present invention and an androgen receptor modulator. Another preferred combination is a compound of the present invention and an osteoblast anabolic agent.
  • the formula I agonists generally have an EC50 value from about 0.001 nM to about 100 microM, although agonists with activities outside this range can be useful depending upon the dosage and route of administration.
  • the agonists have an EC50 value of from about 0.01 rnicroM to about 10 microM.
  • the agonists have an EC50 value of from about 0.1 microM to about 10 microM.
  • EC5 Q is a common measure of agonist activity well known to those of ordinary skill in the art and is defined as the concentration or dose of an agonist that is needed to produce half, i.e. 50%, of the maximal effect.
  • the compounds of this invention can be made, with some modification, in accordance with US Patent No. 6,043,275, EP0855389, WO 03/047417 (USSN 60/337228), WO 03/047513 (USSN 60/338,117), USSN 60/406,530 (Merck Docket No. MC060) and WO 01/46140, all of which are incorporated herein by reference in their entirety.
  • the following non- limiting schemes and examples given by way of illustration is demonstrative of the present invention.
  • N-BOC-pipecolinic acid (166.5 g, 726 mmoles) in 500 mL dimethylformamide (DMF) was added Mel (123.7 g, 871 mmoles) and 2 CO 3 (100.4 g, 726 moles).
  • the reaction mixture slowly exothermed to 40 °C after 0.5h during a 4h age period at ambient temperature.
  • MTBE (830 mL) and then washed with H 2 O (2 x 830mL) and 20% brine (300 mL).
  • the organic layer was dried over Na 2 SO and concentrated to an oil (3).
  • the organic layer was then treated with saturated Na 2 CO 3 (25 mL), brine, dried over MgSO 4 , filtered and concentrated in vacuo.
  • the resulting crude oil (9) is used directly in the next step.
  • the alcohol can be purified by SiO 2 gel flash column chromatography (40:1 CH 2 Cl 2 :MeOH).
  • reaction mixture was then poured slowly into a mixture of ice/H 2 O (NOTE: exothermic!) and the product was extracted with MTBE (3x).
  • the combined organic layer was then neutralized slowly to a pH of 7 with a cold solution of 20% aqueous Na 2 COs (NOTE: gas evolution), washed with brine, dried over MgSO , filtered and concentrated in vacuo.
  • the reaction mixture was aged at -78 °C for lh, slowly warmed to RT and concentrated to about a quarter of its original volume and added MTBE (400mL) over 0.5h.
  • the resulting suspension was further aged at RT for 0.5h and filtered.
  • the wet cake was washed with MTBE (lOOmL) and dried in vacuo under a stream of N 2 .
  • the product was isolated as white solid (14).
  • the filtrate was diluted with MTBE (1250 mL), sat'd brine (1 L), and water (500mL), with the temperature maintained ⁇ 30° C. Upon transfer to a separatory funnel, the phases were allowed lh to settle and the aqueous layer was cut. The organic layer was washed with sat'd. Na 2 CO 3 (2 x 1L), or until the aq. cut remained basic. The solution was diluted with hexanes (1.25 L) and dried over Na 2 SO 4 for 1 h. The solvent was removed under vacuum and the oil was vacuum distilled to yield pure ester (16). (bp 125 ° @ 4 mm Hg)
  • reaction mixture was then aged at RT for 2h, at which a complete consumption of starting material was observed.
  • Tert-butyl methyl ether - MTBE (5 mL) was added followed by IN HC1 (2mL).
  • the organic layer was separated, washed with saturated Na 2 CO 3 , brine, dried over MgSO 4 , filtered and concentrated in vacuo to give the final compound as viscous oil.
  • the catalyst can also be generated in situ by mixing 0.02 mol equiv of [RuCl (p-cymene) 2 ] and 0.04 mol equiv of the ( ?,i?)-N-Tosyl-l,2-di ⁇ henylethylene-l,2-diamine in DCM (dichloromethane) in the presence of 0.04 mol equiv of 1M solution KOtBu in THF(tetrahydrofuran). After aging for 10 min at RT, Et 3 N was added followed by HCO 2 H and a solution of the enone in DCM).
  • the catalyst was prepared by mixing lmol equiv of [RuCl 2 (p-cymene) 2 ], 2mol equiv (R,R)-N- Tosyl-l,2-di ⁇ henylethylene-l,2-diamine and 4.2 mol equiv of Et 3 N in iPrOH at 80 °C for lh(hour). After solvent removal, the solid was washed with cold H 2 O and the recrystallized from MeOH to give the catalyst as orange solid.
  • Step 1 isopropyl 7-[(2R)-2-( ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ methyl)-6-oxopiperidin-l-yl]heptanoi
  • Step 2 isopropyl 7-[(2i?)-2-(hydroxymethyl)-6-oxopiperidin-l-yl]heptanoate
  • Step 3 isopropyl 7- ⁇ (2R)-2-[(lE)-4,4-difluoro-3-oxo-4-phenylbut-l-en-l-yl]-6-
  • Triethyl amine (0.31 g, 0.43 mL, 3.1 mmol) was added dropwise and after 15 min of stirring was concentrated in vacuo without the use of the bath. A solution of 1:1 diethyl ether/ethyl acetate (100 mL) was used to filter off the triethylamine salts and the solution was concentrated in vacuo.
  • the crude aldehyde, 10 was then diluted in 5 mL of THF and added to a solution of (2-oxo-3-phenyl-propyl)-phosphonic acid dimethyl ester (0.34 g, 1.4 mmol) and 60% sodium hydride (52 mg, 1.3 mmol) in 15 mL of THF at 0 °C which had been premixed 1 hour.
  • Zinc chloride x mL of a 1M solution in THF was added
  • the solution was quenched with saturated aqueous ammonium chloride solution and was extracted with ethyl acetate.
  • Step 4 isopropyl 7- ⁇ (2i?)-2-[(lE,3i?)-4,4-difluoro-3-hydroxy-4-phenylbut-l-en-l-yl]-6- oxopiperidin- 1 -yl ⁇ heptanoate
  • the mixture was extracted with ethyl acetate (emulsion developed during extraction and the suspension was filtered through celite to remove emulsion).
  • the crude product was purified by flash chromatograph. Eluting with EA/hexanes (70-100%) gave the desired alcohol as a mixture of two diastereomers in a ratio of 12:1.
  • the mixture was easily separated by prep HPLC (high performance liquid chromatograpy) using a chiral Pak AD ® column using 50% iPrOH in hexanes as eluants (monitoring at ⁇ 214 nm). The undesired isomer came out first followed by the desired isomer 12.
  • Step 5 7- ⁇ (2i?)-2-[(lE, 3R)-4,4-difluoro-3-hydroxy-4-phenylbut-l-en-l-yl]-6-oxopiperidin-l- yi ⁇ heptanoic acid
  • Example 9 isopropyl 5- ⁇ 3-[(2R)-2-((lE)-(3S) 3-hydroxy-4-phenyl-but-l-enyl)-6-oxo-piperidin-l-yl]- propyl ⁇ -thiophene-2-carboxylate 1H NMR (400 MHz, CDC1 3 ): ⁇ 7.6 (d, IH), 7.3-7.1 (m, 5H), 6.8 (d, IH), 5.5 (m, 2H), 5.1 (m, IH), 4.4 (m, IH), 3.9-3.8 (m, 2H), 3.3 (br s, IH), 2.8 (m, 4H), 2.7 (m, IH), 2.3 (m, 2H), 1.9-1.6 (m, 6H), 1.3 (dd, 6H); MS (+ESI):
  • Example 10 isopropyl 5- ⁇ 3-[(2R)-2-((35) 3-hydroxy-4-phenyl-butyl)-6-oxo-piperidin-l-yl]-propyl ⁇ - thiophene-2-carboxylate
  • Example 12 isopropyl (5Z)-7- ⁇ (2R)-2-[(lE,3R)-4,4-difluoro-3-hydroxy-4-phenylbut-l-en-l-yl]-6- oxopiperidin-l-yl ⁇ hept-5-enoate
  • Example 14 isopropyl-7- ⁇ (4i?)-4-[(lE)-4,4-difluoro-3-hydroxy -4-phenylbut- 1 -en-yl] -2-oxo -1,3-oxanzinan-
  • Step 8 Preparation of isopropyl 7- ⁇ (4i?)-4-[(lE)-4,4-difluoro-3-oxo-4-phenylbut-l-en-l-yl]-2-oxo-l,3- oxazinan-3-yl ⁇ heptanoate
  • the isopropyl ester Compound 29 was first treated with a mixture of LiOH in Methanol/water followed by acidification with IN HCl and extraction with ethyl acetate to give title compound.
  • IOP Intraocular Pressure
  • Drug concentrations are expressed in terms of the active ingredient (base).
  • the compounds of this invention are dissolved in physiological saline at 0.01, 0.001, 0.0001 % for rabbit study and 0.05, 0.005% for monkey studies.
  • Drug or vehicle aliquots (25 ul) are administered topically unilaterally or bilaterally. In unilateral applications, the contralateral eyes receive an equal volume of saline.
  • Proparaeaine (0.5%) is applied to the cornea prior to tonometry to minimize discomfort.
  • Intraocular pressure (IOP) is recorded using a pneumatic tonometer (Alcon Applanation Pneumatonograph) or equivalent. Analysis
  • results are expressed as the changes in IOP from the basal level measured jusl prior to administration of drug or vehicle and represent the mean, plus or minus standard deviation.
  • Statistical comparisons are made using the Student's t-test for non-paired data between responses of drug-treated and vehicle-treated animals and for paired data between ipsilateral and contralateral eyes at comparable time intervals.
  • the significance of the date is also determined as the difference from the "t-0" value using Dunnett's "t” test. Asterisks represent a significance level of p ⁇ 0.05.
  • IOP is measured before treatment then the compounds of this invention or vehicle are instilled (one drop of 25 ul) into one or both eyes and IOP is measured at 30, 60, 120, 180, 240, 300, and 360 minutes after instillation. In some cases, equal number of animals treated bilaterally with vehicle only are evaluated and compared to drug treated animals as parallel controls.
  • Unilateral ocular hypertension of the right eye is induced in female cynomolgus monkeys weighing between 2 and 3 kg by photocoagulation of the trabecular meshwork with an argon laser system (Coherent NOVUS 2000, Palo Alto, USA) using the method of Lee at al. (1985).
  • IOP intraocular pressure
  • IOP measurements the monkeys are kept in a sitting position in restraint chairs for the duration of the experiment. Animals are lightly anesthetized by the intramuscular injection of ketamine hydrochloride (3-5 mg/kg) approximately five minutes before each IOP measurement and one drop of 0.5% proparaeaine was instilled prior to recording IOP. IOP is measured using a pneumatic tonometer (Alcon Applanation Tonometer) or a Digilab pneumatonometer (Bio-Rad Ophthalmic Division, Cambridge, MA, USA).
  • IOP is measured before treatment and generally at 30, 60, 124, 180, 300, and 360 minutes after treatment. Baseline values are also obtained at these time points generally two or three days prior to treatment. Treatment consists of instilling one drop of 25 ul of the compounds of this invention (0.05 and 0.005 %) or vehicle (saline). At least one-week washout period is employed before testing on the same animal. The normotensive (contralateral to the hypertensive) eye is treated in an exactly similar manner to the hypertensive eye. IOP measurements for both eyes are compared to the corresponding baseline values at the same time point. Results are expressed as mean plus-or-minus standard deviation in mm Hg. The activity range of the compounds of this invention for ocular use is between 0.01 and 100,000 nM.
  • Prostanoid receptor (PG) cDNAs corresponding to full length coding sequences were subcloned into the appropriate sites of the mammalian expression vector pCEP4 (Invitrogen) pCEP4PG plasmid DNA was prepared using the Qiagen plasmid preparation kit (QIAGEN) and transfected into HEK 293(EBNA) cells using LipofectAMTNE® (GIBCO-BRL) according to the manufacturers' instructions.
  • HEK 293(EBNA) cells expressing the cDNA together with the hygromycin resistance gene were selected in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10 % heat inactivated fetal bovine serum, 1 mM sodium pyruvate, 100 U/ml Penicillin-G, 100 ⁇ g/ml Streptomycin sulphate, 250 ⁇ g/ml active
  • DMEM Dulbecco's Modified Eagle Medium
  • GENETICrNTM G418) (all from Life Technologies, Inc./BRL) and 200 itg/ml hygromycin (Calbiochem). Individual colonies were isolated after 2-3 weeks of growth under selection using the cloning ring method and subsequently expanded into clonal cell lines. Expression of the receptor cDNA was assessed by receptor binding assays.
  • HEK 293(EBNA) cells were grown in supplemented DMEM complete medium at
  • the 160,000 x g pellets were resuspended in 10 mM HEPES/KOH (pH 7.4) containing 1 mM EDTA at approximately 5-10 mg/ml protein by Dounce homogenisation (Dounce A; 10 strokes), frozen in liquid nitrogen and stored at -80°C.
  • Prostanoid receptor binding assays were performed in a final incubation volume of 0.2 ml in 10 mM MES/KOH (pH 6.0) (EP subtypes, FP and TP) or 10 mM HEPES/KOH (pH 7.4) (DP and IP), containing 1 mM EDTA, 10 mM MgCl 2 (EP subtypes) or 10 mM MnCl 2 (DP, FP, IP and TP) and radioligand [0.5-1.0 nM [ 3 H]PGE 2 (181 Ci/mmol) for EP subtypes, 0.7 nM [ 3 H]PGD 2 (115 Ci/mmol) for DP, 0.95 nM [ 3 H]PGF 2 ⁇ (170 Ci/mmol) for FP, 5 nM [ 3 H]iloprost (16 Ci/mmol) for IP and 1.8 nM [ 3 H]SQ 29548 (46 Ci/mmol) for TP].
  • EP 3 assays also contained 100 ⁇ M GTP ⁇ S.
  • the reaction was initiated by addition of membrane protein (approximately 30 ⁇ g for EP 1; 20 ⁇ g for EP 2 , 2 ⁇ g for EP 3 , 10 ⁇ g for EP 4 , 60 ⁇ g for FP, 30 ⁇ g for DP, 10 ⁇ g for IP and 10 ⁇ g for TP) from the 160,000 x g fraction.
  • Ligands were added in dimethylsulf oxide (Me 2 SO) which was kept constant at 1 % (v/v) in all incubations. Non-specific binding was determined in the presence of 1 ⁇ M of the corresponding non-radioactive prostanoid.
  • Incubations were conducted for 60 min (EP subtypes, FP and IP) or 30 min (DP and TP) at 30°C (EP subtypes, DP, FP and TP) or room temperature (IP) and terminated by rapid filtration through a 96-weIl Unifilter GF/C (Canberra Packard) prewetted in assay incubation buffer without EDTA (at 4°C) and using a Tomtec Mach HJ 96- well semi-automated cell harvester.
  • the filters were washed with 3-4 ml of the same buffer, dried for 90 min at 55 °C and the residual radioactivity bound to the individual filters determined by scintillation counting with addition of 50 ⁇ l of Ultima Gold F (Canberra Packard) using a 1450 MicroBeta ( allac). Specific binding was calculated by subtracting non-specific binding from total binding. Specific binding represented 90-95 % of the total binding and was linear with respect to the concentrations of radioligand and protein used. Total binding represented 5-10 % of the radioligand added to the incubation media.
  • the activity range of the compounds of this invention for bone use is between 0.01 and 100,000 nM.
  • 5-week old Sprague-Dawley rats (Charles River) are euthanized by CO2, their tibiae and calvariae are excised, cleaned of soft tissues and frozen immediately in liquid nitrogen.
  • 6-week old rats are given a single injection of either vehicle (7% ethanol in sterile water) or an anabolic dose of PGE2 (Cayman Chemical, Ann Arbor, MI), 3-6 mg/kg in the same vehicle) intraperitoneally.
  • Animals are euthanized at several time points post-injection and their tibiae and calvariae, as well as samples from lung and kidney tissues are frozen in liquid nitrogen.
  • RP-1 periosteal cells are spontaneously immortalized from primary cultures of periosteal cells from tibae of 4- week old Sprague-Dawley rats and are cultured in DMEM (BRL, Gaithersburg, MD) with 10 % fetal bovine serum (JRH Biosciences, Lenexa, KS). These cells do not express osteoblastic phenotypic markers in early culture, but upon confluence, express type I collagen, alkaline phosphatase and osteocalcin and produce mineralized extracellular matrix.
  • RCT-1 and RCT-3 are clonal cell lines immortalized by SV-40 large T antigen from cells released from fetal rat calvair by a cmbination collagenase/hyaluronidase digestion.
  • RCT-1 cells derived from cells released during the first 10 minutes of digestion (fraction I), are cultured in RPMI 1640 medium (BRL) with 10% fetal bovine serum and 0.4 mg/ml G418 (BRL). These cells differentiate and express osteoblastic features upon retinoic acid treatment.
  • RCT-3 cells immortalized from osteoblast-enriched fraction HI cells, are cultured in F-12 medium (BRL) with 5% Fetal bovine serum and 0.4 mg/ml G418.
  • TRAB-11 cells are also immortalized by SV40 large T antigen from adult rat tibia and are cultured in RPMI 1640 medium with 10% FBS and 0.4 mg/ml G418.
  • ROS 17/2.8 rat osteosarcoma cells are cultured in F-12 containing 5% FBS.
  • Osteoblast-enriched (fraction TS) primary fetal rat calvaria cells are obtained by collagenase/hyaluronidase dsum of calvariae of 19 day-old rat fetuses. See Rodan et al., Growth stimulation of rat calvaria osteoblastic cells by acidic FGF,
  • Cells are released during 30-50 minutes digestion (fraction 111) and are cultured in F-12 medium containing 5% FBS.
  • P815 mouse mastocytoma cells, cultured in Eagles MEM with 10% FBS
  • NRK normal rat kidney fibroblasts
  • RNA samples (20 mg) 10 are separated on 0.9% agarose/formaldehyde gels and transferred onto nylon membranes (Boehringer Mannheim, Germany).
  • Membranes are prehybridized in Hybrisol I (Oncor, Gaithersburg, MD) and 0.5 mg/ml sonicated salmon sperm DNA (Boehringer) at 42°C for 3 hours and are hybridized at 42°C with rat EP2 and mouse EP4 cDNA probes labeled with [ 32 P]- dCTP (Amersham, Buckinghamshire, UK) by random priming using the rediprime kit 15 (Amersham). After hybridization, membranes are washed 4 times in 2xSSC + 0.1% SDS at room temperature for a total of 1 hour and once with 0.2xSSC + 0.1% SDS at 55°C for 1 hour and then exposed to Kodak XAR 2 film at -70°C using intensifying screens.
  • bound probes are removed twice with 0.1% SDS at 80°C and membranes are hybridized with a human GAPDH (Glyceraldehyde 3-Phosphate Dehydrogenase) cDNA probe 20 (purchased from Clontech, Palo Alto, CA) for loading control.
  • GAPDH Glyceraldehyde 3-Phosphate Dehydrogenase
  • Frozen tibiae are sectioned coronally at 7 mm thickness and sections are mounted on charged slides (Probe On Plus, Fisher Scientific, Springfield, NJ) and are kept at -
  • cRNA probes are labeled with 35 S-UTPgS (ICN, Costa Mesa, CA) using a Riboprobe TJ kit (Pro ega Madison, WT). Hybridization is performed overnight at 50° C. See M. Weinreb et ⁇ l, Different pattern of alkaline phosphatase, osteopontin and osteocalcin expression in developing rat bone visualized by in-situ hybridization, J. Bone Miner Res., 5, 831- 842 (1990) and D. Shinar et al., Expression ofalphav and beta3 integrin subunits in rat
  • EP/ j In Osteoblastic Cell Lines And In Bone Tissue.
  • the expression of EP4 and EP2 mRNA is examined in various bone derived cells including osteoblast-enriched primary rat calvaria cells, immortalized osteoblastic cell lines from fetal rat calvaria or from adult rat tibia and an osteoblastic osteosarcoma cell line. Most of the osteoblastic cells and cell lines show significant amounts of 3.8 kb EP4 mRNA, except for the rat osteosarcoma cell line ROS 17/2.8. Consistent with this finding, in ROS 17/2.8 cells PGE2 has no effect on intracellular cAMP, which is markedly induced in RCT-3 and TRAB-11 cells.
  • EP4 mRNA Treatment of RCT-1 cells with retinoic acid, which promotes their differentiation, reduces the levels of EP4 mRNA.
  • NRK fibroblasts do not express EP4 mRNA, while P815 mastocytoma cells, used as positive controls, express large amounts of EP4 mRNA.
  • EP4 mRNA none of the osteoblastic cells and cell lines express detectable amounts of EP2 mRA in total RNA samples.
  • EP4 mRNA in osteoblastic cells EP4 is also expressed in total RNA isolated from tibiae and calvariae of 5-week-old rats. In contrast, no EP2 mRNA is found in RNA from tibial shafts.
  • PGE2 enhances its own production via upregulation of cyclooxygenase 2 expression in osteoblasts and in bone tissue thus autoamplifying its own effects. PGE2 also increases the levels of EP4 mRNA.
  • RP-1 cells are immortalized from a primary culture of adult rat tibia periosteum is examined. These cells express osteoblast phenotypic markers upon confluence and form mineralized bone matrix when implanted in nude mice. Similar to the other osteoblastic cells examined, RP-1 periosteal cells express a 3.8 kb EP4 transcript. Treatment
  • PGE2 has no ef ect on EP4 RNA levels in the more differentiated RCT-3 cells pointing to cell- type specific regulation of EP4 expression by PGE2.
  • EP2 mRNA is not expressed in RP-1 cells before or after treatment with PGE2.
  • PGE2 regulates EP4 mRNA levels in vivo in bone tissue
  • five- week-old male rats are injected with PGE2 (3 - 6 mg/Kg).
  • Systemic administration of PGE2 rapidly increased EP4 mRNA levels in the tibial diaphysis peaking at 2 h after injection.
  • a similar effect of PGE2 on EP4 mRNA is observed in the tibial metaphysis and in calvaria.
  • PGE2 induces EP4 mRNA levels in vitro in osteogenic periosteal cells and in vivo in bone tissue in a cell type-specific and tissue-specific manner.
  • PGE2 does not induce EP2 mRNA in RP-1 cells nor in bone tissue.
  • In situ hybridization is used in order to localize cells expressing EP4 in bone.
  • control experiment vehicle-injected rats
  • low expression of EP4 is detected in bone marrow cells.
  • Administration of a single anabolic dose of PGE2 increased the expression of EP4 in bone marrow cells.
  • the distribution of silver grains over the bone marrow is not uniform and occurs in clumps or patches in many areas of the metaphysis. Within the tibial metaphysis, EP4 expression is restricted to the secondary spongiosa area and is not seen in the primary spongiosa.
  • EP4 is expressed in osteoblastic cells in vitro and in bone marrow cells in vivo, and is upregulated by its ligand, PGE2.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP04723484A 2003-03-26 2004-03-26 Prostaglandin analoge als ep4 rezeptor agonisten Expired - Lifetime EP1613621B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45770003P 2003-03-26 2003-03-26
PCT/CA2004/000470 WO2004085430A1 (en) 2003-03-26 2004-03-26 Prostaglandin analogs as ep4 receptor agonists

Publications (2)

Publication Number Publication Date
EP1613621A1 true EP1613621A1 (de) 2006-01-11
EP1613621B1 EP1613621B1 (de) 2010-07-21

Family

ID=33098243

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04723484A Expired - Lifetime EP1613621B1 (de) 2003-03-26 2004-03-26 Prostaglandin analoge als ep4 rezeptor agonisten

Country Status (22)

Country Link
US (4) US7053085B2 (de)
EP (1) EP1613621B1 (de)
JP (1) JP4866992B2 (de)
KR (1) KR20060002873A (de)
CN (1) CN1764659A (de)
AR (1) AR040806A1 (de)
AT (1) ATE474837T1 (de)
BR (1) BRPI0408690A (de)
CA (1) CA2519938C (de)
CL (1) CL2004000655A1 (de)
DE (1) DE602004028229D1 (de)
EC (1) ECSP056037A (de)
ES (1) ES2347434T3 (de)
HR (1) HRP20050845A2 (de)
IS (1) IS7999A (de)
MA (1) MA27667A1 (de)
MX (1) MXPA05010189A (de)
NO (1) NO20054951L (de)
PE (1) PE20050522A1 (de)
RU (1) RU2005132930A (de)
TW (1) TW200427670A (de)
WO (2) WO2004085430A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
JP2006515015A (ja) * 2003-01-10 2006-05-18 エフ.ホフマン−ラ ロシュ アーゲー プロスタグランジンアゴニストとしての2−ピペリドン誘導体
US6977260B2 (en) 2004-01-22 2005-12-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
WO2004108215A1 (en) * 2003-06-06 2004-12-16 Allergan, Inc. Piperidinyl prostaglandin e analogs
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7326716B2 (en) 2003-06-06 2008-02-05 Allergan, Inc. Treatment of inflammatory bowel disease
JP2007504228A (ja) 2003-09-02 2007-03-01 メルク エンド カムパニー インコーポレーテッド 高眼圧症を治療するための眼組成物
JP4546961B2 (ja) 2003-09-04 2010-09-22 メルク・シャープ・エンド・ドーム・コーポレイション 高眼圧の治療のための眼科用組成物
CN1842335A (zh) 2003-09-04 2006-10-04 默克公司 用于治疗高眼压的眼用组合物
EP1771427A1 (de) 2004-07-02 2007-04-11 Allergan Inc. Prostaglandinanaloga
CA2574078A1 (en) * 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US20080132543A1 (en) * 2004-10-26 2008-06-05 Wha Bin Im Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists
WO2006052630A1 (en) * 2004-11-04 2006-05-18 Allergan, Inc. Therapeutic substituted piperidone compounds
CN101133037B (zh) * 2005-01-27 2012-05-09 旭化成制药株式会社 六元杂环化合物及其用途
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
AU2006275263A1 (en) * 2005-08-03 2007-02-08 Merck Frosst Canada Ltd EP4 receptor agonist, compositions and methods thereof
AU2006275270A1 (en) * 2005-08-03 2007-02-08 Merck Frosst Canada Ltd EP4 receptor agonist, compositions and methods thereof
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US7550448B2 (en) 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
US7498447B2 (en) 2006-05-24 2009-03-03 Allergan, Inc. Therapeutic compounds
WO2008027341A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
WO2008070310A2 (en) 2006-10-20 2008-06-12 Children's Medical Center Corporation Method to enhance tissue regeneration
CN101168514B (zh) * 2006-10-26 2011-12-07 上海药明康德新药开发有限公司 光学活性α-氨基辛二酸酯和α-氨基辛二酸单酯的合成方法
BRPI0720254A2 (pt) 2006-12-15 2014-01-07 Glaxo Group Ltd Derivados de benzamida como agonistas do receptor ep4
GB2446652A (en) * 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
MX2009012043A (es) 2007-05-08 2010-02-18 Nat Univ Corp Hamamatsu Activador de celulas t citotoxicas que comprende agonista ep4.
CA2693552A1 (en) * 2007-06-07 2008-12-11 Astellas Pharma Inc. Pyridone compound
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
CN101468985A (zh) * 2007-12-28 2009-07-01 中国人民解放军军事医学科学院毒物药物研究所 5-(3-芳杂环取代苯基)四氮唑类化合物及其抗hiv/aids的应用
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US7964596B2 (en) 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
EP2488168A1 (de) 2009-10-14 2012-08-22 Gemmus Pharma Inc. Kombinationstherapie zur behandlung von virusinfektionen
CA2738045C (en) * 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
WO2016199111A1 (en) 2015-06-12 2016-12-15 Simon Fraser University Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
WO2017126635A1 (ja) * 2016-01-22 2017-07-27 武田薬品工業株式会社 複素環化合物およびその用途
ES2929799T3 (es) 2017-12-25 2022-12-01 Asahi Kasei Pharma Corp Compuestos que contienen resto de 2-oxo-1,3,4-tiadiazinan-3-ilo con actividad agonista del receptor EP4
EP3972599A1 (de) 2019-05-21 2022-03-30 Ardelyx, Inc. Kombination zur senkung des serum-phosphatspiegels bei einem patienten
CN111269193B (zh) * 2020-04-02 2022-05-24 湖南海利常德农药化工有限公司 一种苯并[e][1,3]噁嗪-2,4-二酮的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524818A (en) 1974-11-29 1978-09-13 Beecham Group Ltd 12-azaprostaglandins
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
EP0008186A1 (de) 1978-08-08 1980-02-20 Beecham Group Plc Zyklische Diamide, ein Verfahren zu ihrer Herstellung und ihre pharmazeutischen Zusammensetzungen
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US4960771A (en) * 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ES2186670T3 (es) 1988-09-06 2003-05-16 Pharmacia Ab Derivados de prostaglandina para el tratamiento del glaucoma o la hipertension ocular.
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd 3,7−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
WO2000015608A1 (en) 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. φ-SUBSTITUTED PHENYL-PROSTAGLANDIN E DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
CA2346031A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
UA72293C2 (en) 1999-12-22 2005-02-15 Pfizer Prod Inc Ep4 receptor selective agonists (variants) for treating conditions presenting with low bone mass and pharmaceutical composition
CN1450994A (zh) 2000-03-17 2003-10-22 爱尔康公司 用于治疗青光眼的6-羟基-吲唑衍生物
WO2001072268A1 (fr) 2000-03-31 2001-10-04 Toray Industries, Inc. Agents de régulation de la pousse du cheveu ou de sa formation
WO2002024647A1 (fr) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
NZ525164A (en) 2000-11-27 2005-04-29 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
CA2434495A1 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2002077168A2 (en) 2001-03-22 2002-10-03 Merck & Co., Inc. Mch1r deficient mice
WO2003047417A2 (en) 2001-12-03 2003-06-12 Merck & Co., Inc. Ep4 receptor agonist, compositions and methods thereof
WO2003047513A2 (en) 2001-12-03 2003-06-12 Merck & Co., Inc. Method for treating ocular hypertension
US20050256117A1 (en) 2002-06-14 2005-11-17 Meng Hsin Chen Ophthalmic compositions for treating ocular hypertension
AU2003245531A1 (en) 2002-06-17 2003-12-31 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
CA2488752A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
JP2006515015A (ja) 2003-01-10 2006-05-18 エフ.ホフマン−ラ ロシュ アーゲー プロスタグランジンアゴニストとしての2−ピペリドン誘導体
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004085430A1 *

Also Published As

Publication number Publication date
HRP20050845A2 (en) 2006-05-31
ATE474837T1 (de) 2010-08-15
DE602004028229D1 (de) 2010-09-02
CN1764659A (zh) 2006-04-26
AU2004224261A1 (en) 2004-10-07
EP1613621B1 (de) 2010-07-21
MA27667A1 (fr) 2005-12-01
IS7999A (is) 2005-08-25
NO20054951L (no) 2005-12-22
US20040198701A1 (en) 2004-10-07
TW200427670A (en) 2004-12-16
JP2006520758A (ja) 2006-09-14
NO20054951D0 (no) 2005-10-25
USRE42562E1 (en) 2011-07-19
US20110237511A1 (en) 2011-09-29
ES2347434T3 (es) 2010-10-29
US7238710B2 (en) 2007-07-03
KR20060002873A (ko) 2006-01-09
ECSP056037A (es) 2006-01-27
PE20050522A1 (es) 2005-07-06
JP4866992B2 (ja) 2012-02-01
MXPA05010189A (es) 2006-02-22
BRPI0408690A (pt) 2006-03-28
WO2004085431A1 (en) 2004-10-07
US20050227969A1 (en) 2005-10-13
AR040806A1 (es) 2005-04-20
CL2004000655A1 (es) 2005-01-21
RU2005132930A (ru) 2006-02-10
US7053085B2 (en) 2006-05-30
CA2519938A1 (en) 2004-10-07
WO2004085430A1 (en) 2004-10-07
CA2519938C (en) 2010-11-30

Similar Documents

Publication Publication Date Title
USRE42562E1 (en) EP4 receptor agonist, compositions and methods thereof
US20090270395A1 (en) EP4 Receptor Agonist, Compositions and Methods Thereof
US20090105234A1 (en) EP4 Receptor Agonist, Compositions and Methods Thereof
WO2004019938A1 (en) Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
WO2005116010A1 (en) Ep4 receptor agonist, compositions and methods thereof
WO2004037813A1 (en) Pyrrolidin-2-on derivatives as ep4 receptor agonists
AU2002346561B2 (en) EP4 receptor agonist, compositions and methods thereof
WO2003103664A1 (en) 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
WO2004037786A2 (en) 2-pyrrolidones as ep4 receptor agonists
AU2004224261B2 (en) Prostaglandin analogs as EP4 receptor agonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051026

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAX Requested extension states of the european patent have changed

Extension state: LT

Payment date: 20051026

Extension state: LV

Payment date: 20051026

17Q First examination report despatched

Effective date: 20080212

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LT LV

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SERVOPATENT GMBH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602004028229

Country of ref document: DE

Date of ref document: 20100902

Kind code of ref document: P

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2347434

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100721

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100721

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101122

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101021

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

26N No opposition filed

Effective date: 20110426

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004028229

Country of ref document: DE

Effective date: 20110426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110326

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100721

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: MERCK CANADA INC., CA

Free format text: FORMER OWNER: MERCK FROSST CANADA LTD., CA

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004028229

Country of ref document: DE

Representative=s name: ABITZ & PARTNER PATENTANWAELTE MBB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004028229

Country of ref document: DE

Owner name: MERCK CANADA INC., KIRKLAND, CA

Free format text: FORMER OWNER: MERCK FROSST CANADA LTD., KIRKLAND, QUEBEC H9H 3L1, CA

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: MERCK CANADA INC.

Effective date: 20181123

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: WANNERSTRASSE 9/1, 8045 ZUERICH (CH)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230209

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230310

Year of fee payment: 20

Ref country code: GB

Payment date: 20230208

Year of fee payment: 20

Ref country code: DE

Payment date: 20230210

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230403

Year of fee payment: 20

Ref country code: CH

Payment date: 20230402

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 602004028229

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20240404

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240327

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20240325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240327

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20240325